{"doc_id": "32843098", "type of study": "Therapy", "title": "", "abstract": "High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial.\nThe aim of this study is to explore the effectiveness and safety of high dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to SARS-Cov-2 pneumonia.\nTRIAL DESIGN : Multicentre, randomized clinical trial, controlled, open label, parallel group, to evaluate the effectiveness and safety of high dose dexamethasone in adult patients with confirmed COVID-19, with Acute Respiratory Distress Syndrome.\nWe will include patients with SARS-Cov-2 pneumonia who develop acute respiratory distress syndrome, in several intensive care units (ICU) in Buenos Aires, Argentina (CEMIC, Clinica Bazterrica, Sanatorio Sagrado Corazon) Inclusion criteria: Men and women, age \u2265 18 years old.\nConfirmed diagnosis of SARS-CoV-2 infection, by RT-PCR.\nDiagnosis of Acute Respiratory Distress Syndrome (hypoxemic respiratory failure not explained by cardiac disease + PaO2/FiO2 ratio < 300 with a Positive End-Expiratory Pressure \u2265 5 cm H2O + bilateral pulmonary infiltrates) Length of mechanical ventilation of at least 72 hours Informed consent (next of kin / legal guardian) Exclusion criteria: Pregnant or breast-feeding women.\nTerminal disease (advanced cancer; under palliative care; cardiovascular, respiratory, or renal disease with a life expectancy less \u2264 1 year).\nTherapeutic limitation (advance directives or do not resuscitate order) Severe immunosuppression (HIV infection, long-term use of immunosuppressive agents, active cancer).\nPatients under chronic treatment with glucocorticoids for other diseases (\u2265 8 mg prednisone, or equivalent) Participation in another randomized clinical trial.\nINTERVENTION AND COMPARATOR : Eligible patients will be randomized to receive standard ICU patient care (group 1) or standard ICU patient care plus high dose dexamethasone (group 2).\nGroup 1: dexamethasone up to 6 mg/24 hours for up to 10 days + ventilatory, hemodynamic, nutritional, and antimicrobial support according to international guidelines.\nGroup 2: dexamethasone 16 mg/24 hours for 5 days followed by dexamethasone 8 mg/24 hours for 5 days + ventilatory, hemodynamic, nutritional, and antimicrobial support according to international guidelines.\nMAIN OUTCOME : The main result is ventilator-free days at 28 days (Days without ventilator support in the first 28 days following randomization).\nSecondary outcomes are 28-days and 90-days mortality, frequency of nosocomial infections in the first 28 days after randomization, Sequential Organ Failure Assessment (SOFA) score variation and prone position in the first 10-days, viral shedding 28-days after randomization, and delirium and muscle weakness at ICU discharge.\nTreatment will be assigned according to site stratified randomization by permuted random blocks sequence 1:1 generated with a table in R language concealed in a randomization tool in REDCap (Research Electronic Data CAPture) platform.\nBLINDING (MASKING) : This is an open trial, so no masking of treatment assignment will be used.\nNUMBERS TO BE RANDOMISED (SAMPLE SIZE) :\nAssuming a 3 days difference in ventilator-free days between treatment groups, with a mean of 9 days, and a standard deviation of 9 days; the necessary sample size would be 284 subjects (142 per group), with a power of 80% and a two-tailed alpha error of 0.05.\nTRIAL STATUS : The protocol with code 1264, version 3.0 on date: May 13, 2020 is approved by the local Ethics Committee.\nThe trial is in the recruitment phase.\nRecruitment began May 22, 2020 and is anticipated to be complete by the end of December 2021.\nTRIAL REGISTRATION : The trial was registered under the title \"Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial\" with ClinicalTrials number NCT04395105, https://clinicaltrials.gov/ct2/show/NCT04395105 , registered on 20 May 2020.\nFULL PROTOCOL : The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1).\nIn the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.\n", "Evidence Map": {"Enrollment": [{"term": "Acute Respiratory Distress Syndrome secondary to COVID-19", "negation": "affirmed", "UMLS": {}, "start": 38, "end": 95}, {"term": "Acute Respiratory Distress Syndrome", "negation": "affirmed", "UMLS": {}, "start": 106, "end": 141}, {"term": "SARS-Cov-2 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 155, "end": 175}, {"term": "adult", "negation": "affirmed", "UMLS": {}, "start": 171, "end": 176}, {"term": "confirmed COVID-19", "negation": "affirmed", "UMLS": {}, "start": 191, "end": 209}, {"term": "SARS-Cov-2 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 30, "end": 50}, {"term": "acute respiratory distress syndrome", "negation": "affirmed", "UMLS": {}, "start": 63, "end": 98}, {"term": "SARS-CoV-2 infection", "negation": "affirmed", "UMLS": {}, "start": 23, "end": 43}, {"term": "Acute Respiratory Distress Syndrome", "negation": "affirmed", "UMLS": {}, "start": 13, "end": 48}, {"term": "hypoxemic respiratory failure", "negation": "affirmed", "UMLS": {}, "start": 51, "end": 80}, {"term": "Length", "negation": "negated", "UMLS": {}, "start": 227, "end": 233}, {"term": "mechanical ventilation", "negation": "negated", "UMLS": {}, "start": 237, "end": 259}, {"term": "Terminal disease", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 16}, {"term": "advanced cancer", "negation": "affirmed", "UMLS": {}, "start": 19, "end": 34}, {"term": "care", "negation": "affirmed", "UMLS": {}, "start": 54, "end": 58}, {"term": "cardiovascular , respiratory", "negation": "affirmed", "UMLS": {}, "start": 61, "end": 89}, {"term": "or renal disease", "negation": "affirmed", "UMLS": {}, "start": 92, "end": 108}, {"term": "Severe immunosuppression", "negation": "negated", "UMLS": {}, "start": 74, "end": 98}, {"term": "HIV infection", "negation": "negated", "UMLS": {}, "start": 101, "end": 114}, {"term": "long-term use of", "negation": "negated", "UMLS": {}, "start": 117, "end": 133}, {"term": "chronic treatment with", "negation": "affirmed", "UMLS": {}, "start": 15, "end": 37}, {"term": "glucocorticoids", "negation": "affirmed", "UMLS": {}, "start": 38, "end": 53}, {"term": "other diseases", "negation": "affirmed", "UMLS": {}, "start": 58, "end": 72}, {"term": "COVID-19 Related ARDS", "negation": "affirmed", "UMLS": {}, "start": 82, "end": 103}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19 : a structured summary of a study protocol for a randomised controlled trial .", "Evidence Elements": {"Participant": [{"term": "Acute Respiratory Distress Syndrome secondary to COVID-19", "negation": "affirmed", "UMLS": {}, "start": 38, "end": 95}], "Intervention": [{"term": "High dose dexamethasone", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 23, "has_chemical": [{"text": "dexamethasone", "maps_to": "C0011777:dexamethasone", "start": 10, "end": 23, "has_dosage": ["high dose"]}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "OBJECTIVES", "Text": "The aim of this study is to explore the effectiveness and safety of high dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to SARS-Cov-2 pneumonia .", "Evidence Elements": {"Participant": [{"term": "Acute Respiratory Distress Syndrome", "negation": "affirmed", "UMLS": {}, "start": 106, "end": 141}, {"term": "SARS-Cov-2 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 155, "end": 175}], "Intervention": [{"term": "high dose dexamethasone", "negation": "affirmed", "UMLS": {}, "start": 68, "end": 91, "has_chemical": [{"text": "dexamethasone", "maps_to": "C0011777:dexamethasone", "start": 10, "end": 23, "has_dosage": ["high dose"]}], "has_relation": "N/A"}], "Outcome": [{"term": "effectiveness", "negation": "affirmed", "UMLS": {}, "start": 40, "end": 53}, {"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 58, "end": 64}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "TRIAL DESIGN : Multicentre , randomized clinical trial , controlled , open label , parallel group , to evaluate the effectiveness and safety of high dose dexamethasone in adult patients with confirmed COVID-19 , with Acute Respiratory Distress Syndrome .", "Evidence Elements": {"Participant": [{"term": "adult", "negation": "affirmed", "UMLS": {}, "start": 171, "end": 176}, {"term": "confirmed COVID-19", "negation": "affirmed", "UMLS": {}, "start": 191, "end": 209}], "Intervention": [{"term": "high dose dexamethasone", "negation": "affirmed", "UMLS": {}, "start": 144, "end": 167, "has_chemical": [{"text": "dexamethasone", "maps_to": "C0011777:dexamethasone", "start": 10, "end": 23, "has_dosage": ["high dose"]}], "has_relation": "N/A"}], "Outcome": [{"term": "effectiveness", "negation": "affirmed", "UMLS": {}, "start": 116, "end": 129}, {"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 134, "end": 140}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "PARTICIPANTS", "Text": "We will include patients with SARS-Cov-2 pneumonia who develop acute respiratory distress syndrome , in several intensive care units ( ICU ) in Buenos Aires , Argentina ( CEMIC , Clinica Bazterrica , Sanatorio Sagrado Corazon ) Inclusion criteria : Men and women , age \u2265 18 years old .", "Evidence Elements": {"Participant": [{"term": "SARS-Cov-2 pneumonia", "negation": "affirmed", "UMLS": {}, "start": 30, "end": 50}, {"term": "acute respiratory distress syndrome", "negation": "affirmed", "UMLS": {}, "start": 63, "end": 98}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "PARTICIPANTS", "Text": "Confirmed diagnosis of SARS-CoV-2 infection , by RT-PCR .", "Evidence Elements": {"Participant": [{"term": "SARS-CoV-2 infection", "negation": "affirmed", "UMLS": {}, "start": 23, "end": 43}], "Intervention": [], "Outcome": [{"term": "Confirmed diagnosis", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 19}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "PARTICIPANTS", "Text": "Diagnosis of Acute Respiratory Distress Syndrome ( hypoxemic respiratory failure not explained by cardiac disease + PaO2 / FiO2 ratio < 300 with a Positive End-Expiratory Pressure \u2265 5 cm H2O + bilateral pulmonary infiltrates ) Length of mechanical ventilation of at least 72 hours Informed consent ( next of kin / legal guardian ) Exclusion criteria : Pregnant or breast-feeding women .", "Evidence Elements": {"Participant": [{"term": "Acute Respiratory Distress Syndrome", "negation": "affirmed", "UMLS": {}, "start": 13, "end": 48}, {"term": "hypoxemic respiratory failure", "negation": "affirmed", "UMLS": {}, "start": 51, "end": 80}, {"term": "Length", "negation": "negated", "UMLS": {}, "start": 227, "end": 233}, {"term": "mechanical ventilation", "negation": "negated", "UMLS": {}, "start": 237, "end": 259}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "PARTICIPANTS", "Text": "Terminal disease ( advanced cancer ; under palliative care ; cardiovascular , respiratory , or renal disease with a life expectancy less \u2264 1 year ) .", "Evidence Elements": {"Participant": [{"term": "Terminal disease", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 16}, {"term": "advanced cancer", "negation": "affirmed", "UMLS": {}, "start": 19, "end": 34}, {"term": "care", "negation": "affirmed", "UMLS": {}, "start": 54, "end": 58}, {"term": "cardiovascular , respiratory", "negation": "affirmed", "UMLS": {}, "start": 61, "end": 89}, {"term": "or renal disease", "negation": "affirmed", "UMLS": {}, "start": 92, "end": 108}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "PARTICIPANTS", "Text": "Therapeutic limitation ( advance directives or do not resuscitate order ) Severe immunosuppression ( HIV infection , long-term use of immunosuppressive agents , active cancer ) .", "Evidence Elements": {"Participant": [{"term": "Severe immunosuppression", "negation": "negated", "UMLS": {}, "start": 74, "end": 98}, {"term": "HIV infection", "negation": "negated", "UMLS": {}, "start": 101, "end": 114}, {"term": "long-term use of", "negation": "negated", "UMLS": {}, "start": 117, "end": 133}], "Intervention": [], "Outcome": [{"term": "Therapeutic limitation", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 22}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "PARTICIPANTS", "Text": "Patients under chronic treatment with glucocorticoids for other diseases ( \u2265 8 mg prednisone , or equivalent ) Participation in another randomized clinical trial .", "Evidence Elements": {"Participant": [{"term": "chronic treatment with", "negation": "affirmed", "UMLS": {}, "start": 15, "end": 37}, {"term": "glucocorticoids", "negation": "affirmed", "UMLS": {}, "start": 38, "end": 53}, {"term": "other diseases", "negation": "affirmed", "UMLS": {}, "start": 58, "end": 72}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "INTERVENTION AND COMPARATOR : Eligible patients will be randomized to receive standard ICU patient care ( group 1 ) or standard ICU patient care plus high dose dexamethasone ( group 2 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "standard ICU patient care", "negation": "affirmed", "UMLS": {}, "start": 78, "end": 103, "has_procedure": [{"text": "standard intensive care", "maps_to": "C0085559:intensive care", "start": 0, "end": 23}, {"text": "patient care", "maps_to": "C3853617:patient care", "start": 30, "end": 42}], "has_relation": "N/A"}, {"term": "standard ICU patient care plus high dose dexamethasone", "negation": "affirmed", "UMLS": {}, "start": 119, "end": 173, "has_chemical": [{"text": "dexamethasone", "maps_to": "C0011777:dexamethasone", "start": 58, "end": 71, "has_dosage": ["high dose"]}], "has_procedure": [{"text": "standard intensive care", "maps_to": "C0085559:intensive care", "start": 0, "end": 23}, {"text": "patient care", "maps_to": "C3853617:patient care", "start": 30, "end": 42}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Group 1 : dexamethasone up to 6 mg / 24 hours for up to 10 days + ventilatory , hemodynamic , nutritional , and antimicrobial support according to international guidelines .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "dexamethasone", "negation": "affirmed", "UMLS": {}, "start": 10, "end": 23, "has_chemical": [{"text": "dexamethasone", "maps_to": "C0011777:dexamethasone", "start": 0, "end": 13}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Group 2 : dexamethasone 16 mg / 24 hours for 5 days followed by dexamethasone 8 mg / 24 hours for 5 days + ventilatory , hemodynamic , nutritional , and antimicrobial support according to international guidelines .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "dexamethasone", "negation": "affirmed", "UMLS": {}, "start": 10, "end": 23, "has_chemical": [{"text": "dexamethasone", "maps_to": "C0011777:dexamethasone", "start": 0, "end": 13}], "has_relation": "N/A"}, {"term": "dexamethasone", "negation": "affirmed", "UMLS": {}, "start": 10, "end": 23, "has_chemical": [{"text": "dexamethasone", "maps_to": "C0011777:dexamethasone", "start": 0, "end": 13}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "MAIN OUTCOME : The main result is ventilator-free days at 28 days ( Days without ventilator support in the first 28 days following randomization ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "without ventilator support", "negation": "affirmed", "UMLS": {}, "start": 73, "end": 99, "has_device": [{"text": "ventilator", "maps_to": "C0087153:ventilator", "start": 8, "end": 18, "has_negation": ["without"]}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Secondary outcomes are 28-days and 90-days mortality , frequency of nosocomial infections in the first 28 days after randomization , Sequential Organ Failure Assessment ( SOFA ) score variation and prone position in the first 10-days , viral shedding 28-days after randomization , and delirium and muscle weakness at ICU discharge .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "prone position", "negation": "affirmed", "UMLS": {}, "start": 198, "end": 212, "has_procedure": [{"text": "prone position", "maps_to": "C4551696:Prone position", "start": 0, "end": 14}], "has_relation": "N/A"}], "Outcome": [{"term": "28-days and 90-days mortality", "negation": "affirmed", "UMLS": {}, "start": 23, "end": 52}, {"term": "frequency of nosocomial infections", "negation": "affirmed", "UMLS": {}, "start": 55, "end": 89}, {"term": "Sequential Organ Failure Assessment ( SOFA ) score variation", "negation": "affirmed", "UMLS": {}, "start": 133, "end": 193}, {"term": "viral shedding", "negation": "affirmed", "UMLS": {}, "start": 236, "end": 250}, {"term": "delirium", "negation": "affirmed", "UMLS": {}, "start": 285, "end": 293}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RANDOMISATION", "Text": "Treatment will be assigned according to site stratified randomization by permuted random blocks sequence 1:1 generated with a table in R language concealed in a randomization tool in REDCap ( Research Electronic Data CAPture ) platform .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "BLINDING ( MASKING ) : This is an open trial , so no masking of treatment assignment will be used .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "NUMBERS TO BE RANDOMISED ( SAMPLE SIZE ) :", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Assuming a 3 days difference in ventilator-free days between treatment groups , with a mean of 9 days , and a standard deviation of 9 days ; the necessary sample size would be 284 subjects ( 142 per group ) , with a power of 80 % and a two-tailed alpha error of 0.05 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "days", "negation": "negated", "UMLS": {}, "start": 13, "end": 17}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "TRIAL STATUS : The protocol with code 1264 , version 3.0 on date : May 13 , 2020 is approved by the local Ethics Committee .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "The trial is in the recruitment phase .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Recruitment began May 22 , 2020 and is anticipated to be complete by the end of December 2021 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "TRIAL REGISTRATION : The trial was registered under the title \" Dexamethasone for COVID-19 Related ARDS : a Multicenter , Randomized Clinical Trial \" with ClinicalTrials number NCT04395105 , https:/ / clinicaltrials.gov / ct2 / show / NCT04395105 , registered on 20 May 2020 .", "Evidence Elements": {"Participant": [{"term": "COVID-19 Related ARDS", "negation": "affirmed", "UMLS": {}, "start": 82, "end": 103}], "Intervention": [{"term": "Dexamethasone", "negation": "affirmed", "UMLS": {}, "start": 64, "end": 77, "has_chemical": [{"text": "dexamethasone", "maps_to": "C0011777:dexamethasone", "start": 0, "end": 13}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "FULL PROTOCOL : The full protocol is attached as an additional file , accessible from the Trials website ( Additional file 1 ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "In the interest in expediting dissemination of this material , the familiar formatting has been eliminated ; this Letter serves as a summary of the key elements of the full protocol .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}